1046124-79-1

Usage

Uses

Used in Pharmaceutical Research:
PFI-2 is utilized as a research tool for studying the role of SETD7 in cellular processes and disease development. Its specific inhibition of SETD7 makes it a valuable compound for understanding the biological functions of this enzyme and its involvement in various diseases.
Used in Drug Development:
PFI-2 serves as a potential therapeutic target for conditions related to SETD7 dysregulation. Its chemical structure and properties are being explored for the development of new treatments that target this enzyme, with the aim of addressing diseases like cancer and diabetes.
Used in Chemical Synthesis:
As a member of the sulfonamide class, PFI-2 may also be used in the synthesis of other related compounds for various applications, including the development of new drugs and the study of enzyme inhibition mechanisms.
Used in Diagnostic Applications:
The selective inhibition of SETD7 by PFI-2 could potentially be applied in diagnostic assays to detect the activity of this enzyme in biological samples, which may be indicative of certain disease states or responses to treatment.

Upstream product

• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 106092-09-5 (S)-4,5,6,7-tetrahydrobenzo[d]thiazol-2,6-diamine 

Downstream Products

• 1046124-81-5 (6S)-N-(2-amino-4,5,6,7-tetrahydrobenzothiazole-6-yl)-2-nitro-N-propylbenzenesulfonamide 

Relevant academic research and scientific papers

Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-dia

Our structure-activity relationship studies with N6-(2-(4-(1H-indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivatives led to development of a lead compound (-)-21a which exhibited very hi

A novel scalable synthesis of pramipexole

Pramipexole is a dopamine D2 subfamily receptor agonist that is used for the treatment of Parkinsons disease. We report here on the successful application of the Fukuyama alkylation protocol to the development of a novel and scalable process for synthesis of pramipexole and its pharmaceutically acceptable salts. The synthesis consists of converting the crucial intermediate (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole to (6S)-N-(2-amino-4,5,6,7- tetrahydrobenzothiazole-6-yl)-2-nitrobenzenesulfonamide, which is in turn monoalkylated to (6S)-N-(2-amino-4,5,6,7-tetrahydrobenzothiazole-6-yl)-2-nitro- N-propylbenzenesulfonamide. Deprotection of the latter yields pramipexole base, which is finally converted to a crude pramipexole dihydrochloride monohydrate with a yield of over 50% over four steps. The process allows for the telescoping of the final three steps, has high conversion rates of intermediates, offers ease of purification, and preserves high optical purity throughout all of the stages.

NOVEL PROCESS FOR SYNTHESIS OF PRAMIPEXOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to a novel process for synthesis of pramipexole, shown in the synthesis scheme. Formulae (I), (II), (III), (IV), (V) and (VI).